Berlex Yasmin 20 NDA Filing For Lower Estrogen Dose Slated For Q4
Executive Summary
Schering AG's Berlex subsidiary will highlight Yasmin 20's lower estrogen dose and 24-day hormone treatment regimen in marketing the oral contraceptive
You may also be interested in...
Berlex To Submit Angeliq NDA Response In March, Add Cardioprotective Data
Schering AG's Berlex subsidiary expects to complete its response to FDA on its NDA for the hormone replacement therapy Angeliq in March
Berlex To Submit Angeliq NDA Response In March, Add Cardioprotective Data
Schering AG's Berlex subsidiary expects to complete its response to FDA on its NDA for the hormone replacement therapy Angeliq in March
Schering AG contraceptive patch (correction)
Schering AG plans to submit its gestodene/ethinyl estradiol patch for EU approval in 2004. "The Pink Sheet" (1July 14, 2003, p. 9) incorrectly stated the '04 submission would seek U.S. approval...